Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Sentinel Spectrum** is a veterinary pharmaceutical combination product containing milbemycin oxime, lufenuron, and praziquantel. It is administered orally as a chewable tablet for dogs and provides broad-spectrum parasite protection. Milbemycin oxime acts as a macrocyclic lactone anthelmintic preventing heartworm disease (by targeting Dirofilaria immitis) and treating roundworms, hookworms, and whipworms. Lufenuron is an insect development inhibitor (specifically, a benzoylurea derivative) that interferes with flea egg development, preventing flea infestations. Praziquantel is an anticestodal agent used to treat tapeworm infections (including Echinococcus, Taenia, and Dipylidium species). The combination product is primarily indicated for the prevention of heartworm disease, control of flea populations, and treatment and control of intestinal parasite infections in dogs[2][3][9][12].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sentinel spectrum.